We treat a subset of patients with paraneoplastic neurologic disorders, including those with
Yo-mediated paraneoplastic cerebellar degeneration (PCD), the Hu syndrome, which is most
commonly associated with small cell lung cancer (SCLC) - paraneoplastic subacute sensory
neuropathy, encephalomyelitis, limbic encephalopathy, autonomic neuropathy - and the Ri
Syndrome (a.k.a. Paraneoplastic Opsoclonus-Myoclonus Ataxia), as well as those patients
suspected to have a paraneoplastic neurologic disorder but in whom a characteristic antibody
has not yet been identified. Our treatment protocol consists of immune suppression therapy
using tacrolimus (FK506), a potent inhibitor of lymphocyte proliferation that is commonly
used to prevent organ transplant rejection.